Related Experiment Video
Updated: Apr 12, 2026
In Vitro and In Vivo Evaluation of Photocontrolled Biologically Active Compounds - Potential Drug Candidates for Cancer Photopharmacology
Published on: September 29, 2023
An integrin-targeted photoactivatable Pt(IV) complex as a selective anticancer pro-drug: synthesis and
Albert Gandioso1, Evyenia Shaili, Anna Massaguer
1Departament de Química Orgànica and IBUB, Universitat de Barcelona, Barcelona, E-08028, Spain. vmarchan@ub.edu.
Abstract:
A new anticancer agent based on the conjugation of a photoactivatable Pt(IV) pro-drug to a cyclic RGD-containing peptide is described. Upon visible light irradiation, phototoxicity was induced preferentially in SK-MEL-28 melanoma cancer cells overexpressing αVβ3 integrin compared to control DU-145 human prostate carcinoma cells.
Insights
A novel platinum(IV) pro-drug conjugated to a cyclic peptide shows targeted anticancer activity. Visible light activates the drug, preferentially killing melanoma cells that overexpress αVβ3 integrin.
Area of Science:
- Medicinal Chemistry
- Oncology
- Bioconjugation
Background:
- Targeted drug delivery enhances anticancer efficacy.
- Platinum-based drugs are a cornerstone of cancer chemotherapy.
- Integrin αVβ3 is overexpressed in various cancers, including melanoma.
Purpose of the Study:
- To develop a photoactivatable platinum(IV) pro-drug conjugated to a cyclic RGD peptide.
- To evaluate the targeted phototoxicity of this conjugate against cancer cells overexpressing integrin αVβ3.
Main Methods:
- Synthesis of a platinum(IV) pro-drug conjugated to a cyclic RGD peptide.
- Treatment of SK-MEL-28 (melanoma) and DU-145 (prostate) cancer cells.
- Visible light irradiation and assessment of cell viability and phototoxicity.
Main Results:
- The Pt(IV) pro-drug conjugate was successfully synthesized.
- Visible light irradiation induced preferential phototoxicity in SK-MEL-28 cells.
- Melanoma cells overexpressing αVβ3 integrin showed higher sensitivity compared to prostate cancer cells.
Conclusions:
- The RGD-peptide-conjugated Pt(IV) pro-drug is a promising targeted photodynamic anticancer agent.
- Targeting αVβ3 integrin with light-activated platinum drugs offers a strategy for selective melanoma treatment.
- This approach minimizes damage to healthy tissues.
